Parbendazole

Parbendazole

SCHEMBL29409286

CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 8/20 0.82
TUBB P07437 8/20 0.82
TUBA3C P0DPH7 8/20 0.82
TUBA1B P68363 8/20 0.82
TUBA4A P68366 8/20 0.82
TUBB4B P68371 8/20 0.82
TUBB3 Q13509 8/20 0.82
TUBB2A Q13885 8/20 0.82
TUBB8 Q3ZCM7 8/20 0.82
TUBA3E Q6PEY2 8/20 0.82
TUBA1A Q71U36 8/20 0.82
TUBA1C Q9BQE3 8/20 0.82
TUBB6 Q9BUF5 8/20 0.82
TUBB2B Q9BVA1 8/20 0.82
TUBB1 Q9H4B7 8/20 0.82
LMNA P02545 7/20 0.82
CYP1A2 P05177 5/20 0.82
HIF1A Q16665 4/20 0.82
CYP2D6 P10635 1/20 0.82
TSHR P16473 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Parbendazole SCHEMBL259455 1.00 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Parbendazole SCHEMBL27363030 0.90 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Parbendazole SCHEMBL259456 0.90 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL9860002 0.88 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11120640 0.84 TUBB4A (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11667404 0.81 LMNA (0.58) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL19191488 0.80 TUBB4A (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL28753130 0.80 TUBB4A (0.91) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL28753124 0.80 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29511469 0.80 TUBB4A (0.91) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295787-A1 PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2025-09-25 US claimed
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS THE SCRIPPS RESEARCH INSTITUTE 2025-05-22 US claimed
CN-120018779-A Feed and method for controlling infection of central filarial in mammals 碗中动物健康公司 2025-05-16 CN claimed
CN-114436972-B Pabendazole derivative, and preparation method and application thereof 山东大学 2024-02-13 CN claimed
CN-117043161-A Methods and pharmaceutical compositions for treating diseases 苏州同力生物医药有限公司 2023-11-10 CN claimed
CN-111208283-B Synergistic tumor inhibiting composition and application thereof 中国科学院分子细胞科学卓越创新中心 2023-09-26 CN claimed
CN-116705193-A Screening method of repositioning candidate medicine and application thereof 长沙金域医学检验实验室有限公司 2023-09-05 CN claimed
CN-116368384-A Compounds, targets and pathways for macrophage modulation 麻省理工学院 2023-06-30 CN claimed
EP-3021832-B9 PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-03-15 EP claimed
CN-114436972-A Pabendazole derivative and preparation method and application thereof 山东大学 2022-05-06 CN claimed
EP-3599855-B1 DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS Champion USA LLC (US) 2022-03-02 EP claimed
CN-122036637-A Polymorphs 先正达农作物保护股份公司 2026-05-15 CN disclosed
EP-4676479-A1 PARBENDAZOLE FOR USE IN THE TREATMENT OF DEMENTIA Trustlife Global Inc. (US) 2026-01-14 EP disclosed
EP-4676479-A1 PARBENDAZOLE FOR USE IN THE TREATMENT OF DEMENTIA Trustlife Global Inc. (US) 2026-01-14 EP disclosed
US-20250295787-A1 PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2025-09-25 US disclosed
CN-114436972-A Pabendazole derivative and preparation method and application thereof 山东大学 2022-05-06 CN disclosed
CN-114436972-A Pabendazole derivative and preparation method and application thereof 山东大学 2022-05-06 CN disclosed
EP-3615540-B1 CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES BAYER AG (DE) 2022-04-27 EP disclosed
EP-3974414-A1 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PESTICIDES Bayer AG (DE) 2022-03-30 EP disclosed
WO-2022053453-A1 AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295787-A1 PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION SI, PIM1, PIM3 TUBB4A 3449/4885TUBB 3183/4885TUBA3C 3130/4885
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS MEF2D, TEAD2, TEAD1 TUBB4A 1513/4885TUBB 1530/4885TUBA3C 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.